All AbMole products are for research use only, cannot be used for human consumption.
BMS-754807 is a potent and reversible inhibitor of the type-1 insulin-like growth factor receptor family kinases (Ki, <2 nmol/L). BMS-754807 effectively inhibits the growth of a broad range of human tumor types in vitro, including mesenchymal, epithelial and hematopoietic tumor cell lines (IC50, 5-365 nmol/L). In vitro, BMS-754807 showed a median EC(50) value of 0.62 μM against the PPTP cell lines. BMS-754807 caused apoptosis in a human rhabdomyosarcoma cell line, Rh41, as shown by an accumulation of the sub-G1 fraction, as well as by an increase in poly ADP ribose polymerase and Caspase 3 cleavage. BMS-754807 is active in vivo in multiple xenograft tumor models with tumor growth inhibition ranging from 53% to 115% and at a minimum effective dose of as low as 6.25 mg/kg dosed orally daily. BMS-754807 is currently in phase I development for the treatment of a variety of human cancers.
Neuroreport. 2019 May 22;30(8):580-585.
Insulin attenuates epileptiform discharge-induced oxidative stress by increasing zinc-α2-glycoprotein in primary cultured cortical neurons.
BMS-754807 purchased from AbMole
 |
Source | Int J Mol Sci (2017). Figure 5. BMS-754807 |
| Method | IGF1R/IR and AR antagonists | |
| Cell Lines | TNBC cell | |
| Concentrations | 20 μM | |
| Incubation Time | 48 h | |
| Results | In this panel of TNBC cell lines, inhibition by BMS-754807 consistently induced cell death. These data suggest that inhibitors targeting IGF1R/IR homo- or heterodimers can prevent TNBC tumor growth. |
| Molecular Weight | 461.49 |
| Formula | C23H24FN9O |
| CAS Number | 1001350-96-4 |
| Solubility (25°C) | DMSO 72 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related IGF-1R Products |
|---|
| GSK1904529A
GSK1904529A selectively inhibits IGF-IR and IR with IC50s of 27 and 25 nmol/L, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity. |
| XL228
XL228 is a potent multikinase small-molecule inhibitor of insulin-like growth factor type 1 receptor (IGF1R). |
| OSI-906
OSI-906 (Linsitinib) is a potent, selective, dual ATP-competitive tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with IC50 values of 35 nM and 75 nM respectively. |
| BMS-536924
Bms-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC50 of 100 nM and 73 nM, respectively. It also showed moderate inhibitory activity against Mek, Fak and Lck, but almost no inhibitory activity against Akt1 and MAPK1/2. |
| PQ401
PQ401 is an insulin growth factor-1 receptor (IGF-1R) inhibitor. PQ401 inhibits IGF-I-stimulated IGF-IR autophosphorylation with an IC50 of 12.0 μM in a series of studies in MCF-7 cells. PQ401 is effective at inhibiting IGF-I-stimulated growth of MCF-7 cells (IC50, 6 μM). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
